ReNeuron Group plc
RNUGF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $530 | $403 | $257 | $6,065 |
| % Growth | 31.5% | 56.8% | -95.8% | – |
| Cost of Goods Sold | $4,463 | $8,068 | $9,503 | $16,335 |
| Gross Profit | -$3,933 | -$7,665 | -$9,246 | -$10,270 |
| % Margin | -742.1% | -1,902% | -3,597.7% | -169.3% |
| R&D Expenses | $4,463 | $8,068 | $9,503 | $16,335 |
| G&A Expenses | $1,132 | $1,127 | $728 | $1,914 |
| SG&A Expenses | $1,132 | $1,127 | $3,746 | $1,914 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,413 | -$5,632 | -$9,581 | $2,325 |
| Operating Expenses | $3,182 | $3,563 | $3,668 | $20,574 |
| Operating Income | -$7,115 | -$11,228 | -$12,914 | -$14,409 |
| % Margin | -1,342.5% | -2,786.1% | -5,024.9% | -237.6% |
| Other Income/Exp. Net | $458 | $170 | -$496 | $551 |
| Pre-Tax Income | -$6,657 | -$11,058 | -$13,410 | -$13,858 |
| Tax Expense | -$1,249 | -$1,369 | -$2,063 | -$2,446 |
| Net Income | -$5,408 | -$9,689 | -$11,347 | -$11,412 |
| % Margin | -1,020.4% | -2,404.2% | -4,415.2% | -188.2% |
| EPS | -0.095 | -0.17 | -0.29 | -0.35 |
| % Growth | 44.3% | 41.4% | 17.1% | – |
| EPS Diluted | -0.095 | -0.17 | -0.29 | -0.35 |
| Weighted Avg Shares Out | 57,126 | 56,976 | 39,129 | 32,671 |
| Weighted Avg Shares Out Dil | 57,126 | 56,976 | 39,129 | 32,671 |
| Supplemental Information | – | – | – | – |
| Interest Income | $153 | $29 | $20 | $287 |
| Interest Expense | $20 | $25 | $32 | $42 |
| Depreciation & Amortization | $267 | $324 | $380 | $412 |
| EBITDA | -$6,370 | -$10,709 | -$12,998 | -$13,404 |
| % Margin | -1,201.9% | -2,657.3% | -5,057.6% | -221% |